Trade CHRS anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Coherus Oncology, Inc. (CHRS) is trading at US$1.44, down 1.71% today as of Aug 28, 10:44 EDT. The company has a market capitalisation of US$219.39M. Over the past 52 weeks, CHRS has traded between US$1.09 and US$2.62. On Syfe you can trade CHRS with $0 commission and add it to your watchlist.
| Previous close | US$1.46 |
|---|---|
| Market cap | US$219.39M |
| 52-week range | US$1.09 – US$2.62 |
| Volume | 787.86K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Coherus Oncology, Inc.
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Year: 2014
Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics
Jun 23, 7:07 PM · MT Newswires
Coherus BioSciences Q4 Non-GAAP Loss Unchanged, Revenue Increases
Mar 9, 8:52 PM · MT Newswires
Coherus Oncology, Inc. (CHRS) stock is trading at US$1.44, -1.71% from the previous close of US$1.46.
The market cap for Coherus Oncology, Inc. (CHRS) stock is approximately US$219.39M.
The 52-week high for Coherus Oncology, Inc. (CHRS) stock is US$2.62.
The 52-week low for Coherus Oncology, Inc. (CHRS) stock is US$1.09.
Coherus Oncology, Inc. (CHRS) does not currently pay a dividend.
Stay on top of CHRS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
